NASDAQ:CASI - CASI Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 163.16 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.90
▲ +0.02 (1.06%)
1 month | 3 months | 12 months
Get New CASI Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CASI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CASI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.00
▲ +163.16% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CASI Pharmaceuticals in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 163.16% upside from the last price of $1.90.
Buy
The current consensus among 1 polled investment analysts is to buy stock in CASI Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2020OppenheimerReiterated RatingBuy$5.00High
i
10/23/2020OppenheimerInitiated CoverageOutperform$5.00High
i
3/24/2020HC WainwrightReiterated RatingBuy$7.00 ➝ $3.50Medium
i
5/16/2019HC WainwrightReiterated RatingBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/21/2018HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/4/2018HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/29/2018HC WainwrightReiterated RatingBuy$4.50High
i
Rating by S. Ramakanth at HC Wainwright
1/16/2018HC WainwrightReiterated RatingBuy$5.00High
i
Rating by S. Ramakanth at HC Wainwright
11/14/2017Maxim GroupSet Price TargetBuy$4.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
9/8/2017HC WainwrightReiterated RatingBuy$2.00Medium
i
9/8/2017Maxim GroupReiterated RatingBuy$4.00High
i
Rating by Gabrielle Zhou at Maxim Group
8/14/2017Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Gabrielle Zhou at Maxim Group
5/16/2017Maxim GroupSet Price TargetBuy$4.00Low
i
Rating by Gabrielle Zhou at Maxim Group
4/17/2017Maxim GroupReiterated RatingBuy$4.00Low
i
Rating by Gabrielle Zhou at Maxim Group
3/31/2017Maxim GroupReiterated RatingBuy$4.00Medium
i
Rating by Gabrielle Zhou at Maxim Group
1/17/2017Maxim GroupSet Price TargetBuy$4.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
12/5/2016Maxim GroupSet Price TargetBuy$4.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
11/16/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by S. Ramakanth at HC Wainwright
11/14/2016Maxim GroupSet Price TargetBuy$4.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
9/21/2016Maxim GroupInitiated CoverageBuy$4.00N/A
i
(Data available from 4/14/2016 forward)
CASI Pharmaceuticals logo
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Read More

Today's Range

Now: $1.90
$1.83
$1.93

50 Day Range

MA: $2.29
$1.88
$2.74

52 Week Range

Now: $1.90
$1.46
$3.90

Volume

763,954 shs

Average Volume

1,181,082 shs

Market Capitalization

$265.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of CASI Pharmaceuticals?

The following equities research analysts have issued research reports on CASI Pharmaceuticals in the last year: Oppenheimer Holdings Inc..
View the latest analyst ratings for CASI.

What is the current price target for CASI Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for CASI Pharmaceuticals in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 163.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting CASI will reach $5.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $5.00 for CASI Pharmaceuticals in the next year.
View the latest price targets for CASI.

What is the current consensus analyst rating for CASI Pharmaceuticals?

CASI Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CASI will outperform the market and that investors should add to their positions of CASI Pharmaceuticals.
View the latest ratings for CASI.

What other companies compete with CASI Pharmaceuticals?

How do I contact CASI Pharmaceuticals' investor relations team?

CASI Pharmaceuticals' physical mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is 240-864-2600 and its investor relations email address is [email protected] The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com.